SCHEMBL11943895

SCHEMBL11943895

O=c1c(OCC2CC2)c(N2CCN(S(=O)(=O)c3cccs3)CC2)cnn1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ GPR119 Q8TDV5 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ USP2 O75604 1/20 0.45
▸ DCTPP1 Q9H773 1/20 0.45
▸ RAB9A P51151 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ THRB P10828 1/20 0.42
▸ JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945015 0.91 MAPT (0.47) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11943888 0.88 MAPT (0.61) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11945016 0.87 MAPT (0.50) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11943890 0.87 MAPT (0.44) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11945008 0.86 MAPT (0.54) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11944424 0.86 SMN1; SMN2 (0.48) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11943887 0.86 MAPK1 (0.53) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11943889 0.86 MAPT (0.53) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11945009 0.85 MAPT (0.48) MAPTTSHRGAAHTTSMN1; SMN2
SCHEMBL11943872 0.85 MAPT (0.52) MAPTTSHRGAAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885TSHR 4729/4885GAA 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback